Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dapsone

FDA-approved product (gel, topical), marketed as Aczone, Dapsone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dapsone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Dermatitis herpetiformis
  • Leprosy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other anti-acne preparations for topical use; Drugs for treatment of lepra
FDA pharmacologic class
Sulfone FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04BA02

Repurposing investigation

Dapsone is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae6.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dapsone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dapsone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

    NCT05984381 · start 2023-08-01

    Registered record
    Registry ID
    NCT05984381
    Conditions
    Bullous Pemphigoid
    Interventions
    Prednisolone; Dapsone; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-08-01
    Completion
    2025-04-01
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBullous Pemphigoid
    InterventionPrednisolone; Dapsone; Methotrexate
    PhasePhase 4
    Registry statusCompleted

  • Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

    NCT05894954 · start 2023-07-31

    Registered record
    Registry ID
    NCT05894954
    Conditions
    Mild Cognitive Impairment; Dementia, Mild
    Interventions
    Precision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-07-31
    Completion
    2026-02-09
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Dementia, Mild
    InterventionPrecision Medicine Approach; Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises; Standard-of-Care; Lifestyle including diet, exercise, stress management
    PhasePhase 3
    Registry statusCompleted

  • Dermatitis Herpetiformis Refractory to Gluten Free Diet

    NCT05998291 · start 2023-06-15

    Registered record
    Registry ID
    NCT05998291
    Conditions
    Dermatitis Herpetiformis
    Interventions
    Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2023-06-15
    Completion
    2026-12-31
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis Herpetiformis
    InterventionAssessment of prognosis of refractory dermatitis herpetiformis. No intervention
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Effect of New Topical Preparation for Treatment of Acne Vulgaris

    NCT05899699 · start 2023-06-05

    Registered record
    Registry ID
    NCT05899699
    Conditions
    Acne Vulgaris
    Interventions
    DAP-FLU ME; Adapalene .1% gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-05
    Completion
    2023-10-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDAP-FLU ME; Adapalene .1% gel
    PhasePhase 2
    Registry statusUnknown

  • DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS

    NCT05296460 · start 2022-09-01

    Registered record
    Registry ID
    NCT05296460
    Conditions
    Acne Vulgaris
    Interventions
    Dapsone gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-09-01
    Completion
    2023-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDapsone gel
    PhasePhase 4
    Registry statusUnknown

  • Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris

    NCT05926869 · start 2022-08-01

    Registered record
    Registry ID
    NCT05926869
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin and Dapsone gel for 03 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2023-02-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin and Dapsone gel for 03 months
    PhasePhase 2
    Registry statusCompleted

  • Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

    NCT04935476 · start 2021-11-22

    Registered record
    Registry ID
    NCT04935476
    Conditions
    COVID-19
    Interventions
    Dapsone 85 mg PO BID; Placebo 85 mg PO BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-11-22
    Completion
    2022-07-31
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionDapsone 85 mg PO BID; Placebo 85 mg PO BID
    PhasePhase 3
    Registry statusUnknown

  • Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

    NCT04918914 · start 2020-10-18

    Registered record
    Registry ID
    NCT04918914
    Conditions
    SARS-CoV-2; Hypoxia; ARDS
    Interventions
    Dapsone 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2020-10-18
    Completion
    2021-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS-CoV-2; Hypoxia; ARDS
    InterventionDapsone 100 MG
    PhaseEarly phase 1
    Registry statusUnknown

  • Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

    NCT04015375 · start 2019-07-11

    Registered record
    Registry ID
    NCT04015375
    Conditions
    Acne Vulgaris
    Interventions
    Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd); ACZONE® (dapsone) gel, 7.5% (Allergan, INC.); Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-11
    Completion
    2020-02-22
    Enrolment
    1,150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDapsone gel 7.5% (Torrent Pharmaceuticals Ltd); ACZONE® (dapsone) gel, 7.5% (Allergan, INC.); Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
    PhasePhase 3
    Registry statusCompleted

  • Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

    NCT03681470 · start 2019-04-09

    Registered record
    Registry ID
    NCT03681470
    Conditions
    Acne Vulgaris
    Interventions
    Aczone Gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-04-09
    Completion
    2021-05-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionAczone Gel
    PhasePhase 4
    Registry statusCompleted

  • A Randomized Multicenter Study for Isolated Skin Vasculitis

    NCT02939573 · start 2017-01-01

    Registered record
    Registry ID
    NCT02939573
    Conditions
    Primary Cutaneous Vasculitis; Cutaneous Polyarteritis Nodosa; IgA Vasculitis; Henoch-Schönlein Purpura
    Interventions
    Colchicine; Dapsone; Azathioprine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2017-01-01
    Completion
    2028-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Cutaneous Vasculitis; Cutaneous Polyarteritis Nodosa; IgA Vasculitis; Henoch-Schönlein Purpura
    InterventionColchicine; Dapsone; Azathioprine
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

    NCT02959970 · start 2016-10-31

    Registered record
    Registry ID
    NCT02959970
    Conditions
    Acne Vulgaris
    Interventions
    dapsone gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10-31
    Completion
    2018-03-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventiondapsone gel
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris

    NCT02944461 · start 2016-10

    Registered record
    Registry ID
    NCT02944461
    Conditions
    Acne
    Interventions
    Dapsone 7.5 % gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10
    Completion
    2017-09-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne
    InterventionDapsone 7.5 % gel
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia

    NCT02627417 · start 2015-12

    Registered record
    Registry ID
    NCT02627417
    Conditions
    Adult Immune Thrombocytopenia (ITP); Dapsone
    Interventions
    Dapsone (Disulone®); Prednisone (Cortancyl®) alone followed by monitoring and "standard of care"; Prednisone (Cortancyl®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2019-05
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Immune Thrombocytopenia (ITP); Dapsone
    InterventionDapsone (Disulone®); Prednisone (Cortancyl®) alone followed by monitoring and "standard of care"; Prednisone (Cortancyl®)
    PhasePhase 3
    Registry statusUnknown

  • Photoallergy Potential of Dapsone Gel in Healthy Volunteers

    NCT02117739 · start 2014-04

    Registered record
    Registry ID
    NCT02117739
    Conditions
    Healthy Volunteers
    Interventions
    dapsone gel; dapsone gel vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-07
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventiondapsone gel; dapsone gel vehicle
    PhasePhase 1
    Registry statusCompleted